-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Akanda To Supply Tetra Bio-Pharma With Cannabis For FDA Trials Of Cancer-Pain Drug
Akanda To Supply Tetra Bio-Pharma With Cannabis For FDA Trials Of Cancer-Pain Drug
Akanda Corp. (NASDAQ:AKAN) will supply Tetra Bio-Pharma (OTCQB:TBPMF) (TSX:TBP) (FRA:JAM1) with pharmaceutical grade cannabis flower in a microdose cap form, for use in a Storz & Bickel Mighty Medic Vaporizer for global commercialization of Tetra's QIXLEEF and related products.
In addition, Akanda will act as a contract development and manufacturing organization (CDMO) for Tetra's clinical drug and commercial supply programs. With this project, Akanda becomes a CDMO in addition to being an EU GMP cannabis manufacturer, marking Akanda's first entry into cannabinoid drug development, which is a new and growing market opportunity for the company.
QIXLEEF is a proprietary botanical inhaled investigational new drug currently being studied in two U.S. Food and Drug Administration authorized clinical trials: 1) REBORN 1, a Phase 2 study authorized by the FDA to evaluate inhaled cannabinoids against a class of immediate-release oral opioids for the management of breakthrough cancer pain, and 2) PLENITUDE, a Phase 2 multicenter clinical trial authorized by the FDA to evaluate the safety and efficacy of inhaled cannabinoids to relieve uncontrolled pain in patients with advanced cancer.
Under the multi-year agreement, Akanda will supply Tetra with quality, premium THC and CBD flower, and will provide regulatory, quality and pharmaceutical manufacturing services for the QIXLEEF clinical drug development and marketing authorization from its Portugal operations.
"This supply agreement with Tetra is a major milestone in Akanda's journey in becoming a cannabis platform company serving all regulated markets in the EMEA region," stated Tej Virk, CEO of Akanda. "In supporting a terrific partner with a mission to improve patient health and quality of life though cannabinoid-derived medicine, we are demonstrating that cannabis can fit into the traditional public sector model, with the expectation of reimbursement. Simultaneously, we are productively utilizing our diverse capabilities to support clinical trials for pharma grade cannabinoids. If approved, we expect to provide flower for the authorized compound, potentially creating a significant, incremental revenue stream for Akanda. This opportunity could only have been possible with our state-of-the-art facilities that we gained through the acquisition of Holigen in May."
Meet Akanda's CEO Tej Virk and a slew of other cannabis execs, entrepreneurs, CEOs, investors, etc. at the September Benzinga Cannabis Capital Conference, Sept. 13-14 in Chicago. Get your tickets HERE and reserve your spot at the Palmer House Hotel HERE.
Photo: Courtesy of Business Wire
Related News
Akanda's CanMart Partners With Phlo Connect And Cellen Life Sciences To Strengthen Its Position In UK Medical Cannabis Market
The Flowr Corp. Revenue Grows 64% In 2021, Achieves Record Quarterly Revenue Thanks To This
Halo Collective Q1 2022 Revenue Slightly Drops, Announces Significant Reductions
Akanda Corp. (NASDAQ:AKAN) will supply Tetra Bio-Pharma (OTCQB:TBPMF) (TSX:TBP) (FRA:JAM1) with pharmaceutical grade cannabis flower in a microdose cap form, for use in a Storz & Bickel Mighty Medic Vaporizer for global commercialization of Tetra's QIXLEEF and related products.
阿肯達公司(納斯達克:阿坎)將向利樂生物製藥公司供應(場外交易代碼:TBPMF)(多倫多證券交易所:TBP)(法蘭克福證券交易所:JAM1)含藥用級大麻花以微劑量帽的形式,用於Storz&Bickel公司強大的醫用氣化器利樂的全球商業化奇克利夫以及相關產品。
In addition, Akanda will act as a contract development and manufacturing organization (CDMO) for Tetra's clinical drug and commercial supply programs. With this project, Akanda becomes a CDMO in addition to being an EU GMP cannabis manufacturer, marking Akanda's first entry into cannabinoid drug development, which is a new and growing market opportunity for the company.
此外,阿坎達還將擔任c合同d發展與發展m製造o組織(CDMO)用於利樂的臨牀藥物和商業供應計劃。有了這個項目,Akanda除了成為歐盟GMP大麻製造商外,還成為CDMO,標誌着Akanda第一個進入大麻類藥物開發領域,這對該公司來説是一個新的、不斷增長的市場機會。
QIXLEEF is a proprietary botanical inhaled investigational new drug currently being studied in two U.S. Food and Drug Administration authorized clinical trials: 1) REBORN 1, a Phase 2 study authorized by the FDA to evaluate inhaled cannabinoids against a class of immediate-release oral opioids for the management of breakthrough cancer pain, and 2) PLENITUDE, a Phase 2 multicenter clinical trial authorized by the FDA to evaluate the safety and efficacy of inhaled cannabinoids to relieve uncontrolled pain in patients with advanced cancer.
QIXLEEF是一種專有的植物學吸入性研究新藥,目前正在進行兩項美國食品和藥物管理局授權的臨牀試驗:1)REBURN 1,這是FDA授權進行的第二階段研究,目的是評估吸入性大麻素與一類即刻釋放的口服阿片類藥物治療突破性癌症疼痛的療效;2)Plenity,FDA授權的第二階段多中心臨牀試驗,評估吸入性大麻素緩解晚期癌症患者無法控制的疼痛的安全性和有效性。
Under the multi-year agreement, Akanda will supply Tetra with quality, premium THC and CBD flower, and will provide regulatory, quality and pharmaceutical manufacturing services for the QIXLEEF clinical drug development and marketing authorization from its Portugal operations.
根據多年協議,阿坎達將向利樂提供優質、優質的THC和CBD花卉,並將為QIXLEEF臨牀藥物開發和葡萄牙業務的營銷授權提供監管、質量和製藥製造服務。
"This supply agreement with Tetra is a major milestone in Akanda's journey in becoming a cannabis platform company serving all regulated markets in the EMEA region," stated Tej Virk, CEO of Akanda. "In supporting a terrific partner with a mission to improve patient health and quality of life though cannabinoid-derived medicine, we are demonstrating that cannabis can fit into the traditional public sector model, with the expectation of reimbursement. Simultaneously, we are productively utilizing our diverse capabilities to support clinical trials for pharma grade cannabinoids. If approved, we expect to provide flower for the authorized compound, potentially creating a significant, incremental revenue stream for Akanda. This opportunity could only have been possible with our state-of-the-art facilities that we gained through the acquisition of Holigen in May."
“與利樂的這項供應協議是阿坎達成為一家為歐洲、中東和非洲地區所有受監管市場提供服務的大麻平臺公司之旅中的一個重要里程碑。”Tej Virk,阿坎達公司首席執行官。通過支持一個出色的合作伙伴的使命,通過大麻素衍生藥物改善患者的健康和生活質量,我們證明瞭大麻可以符合傳統的公共部門模式,並期望得到報銷。同時,我們正在有效地利用我們的多樣化能力來支持製藥級大麻類藥物的臨牀試驗。如果獲得批准,我們預計將為授權化合物提供鮮花,可能為阿坎達創造可觀的增量收入來源。只有通過我們在5月份收購Holigen獲得的最先進的設施,才有可能實現這個機會。
Meet Akanda's CEO Tej Virk and a slew of other cannabis execs, entrepreneurs, CEOs, investors, etc. at the September Benzinga Cannabis Capital Conference, Sept. 13-14 in Chicago. Get your tickets HERE and reserve your spot at the Palmer House Hotel HERE.
見面阿坎達的首席執行官Tej Virk以及其他一批大麻高管、企業家、首席執行官、投資者等在9月舉行的本辛加大麻資本會議上。13-14在芝加哥。在這裏拿到票,在這裏預訂您在帕爾默酒店的位置。
Photo: Courtesy of Business Wire
圖片來源:Business Wire提供
Related News
相關新聞
Akanda's CanMart Partners With Phlo Connect And Cellen Life Sciences To Strengthen Its Position In UK Medical Cannabis Market
Akanda‘s CanMart與Phlo Connect和Cellen Life Sciences合作加強其在英國醫用大麻市場的地位
The Flowr Corp. Revenue Grows 64% In 2021, Achieves Record Quarterly Revenue Thanks To This
Flowr Corp.收入在2021年增長64%,實現創紀錄的季度收入
Halo Collective Q1 2022 Revenue Slightly Drops, Announces Significant Reductions
Halo Collect 2022年第一季度收入略有下降,宣佈大幅減少
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧